Novo Nordisk
-
Weight-loss drugmaker Novo Nordisk slims sales forecast
May 9, 2025Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, cut its annual sales forecast on Wednesday, citing a decline in its US market share. Novo Nordisk blamed the revised outlook... -
Novo Nordisk says weight-loss drug Wegovy approved in China
Jun 26, 2024China has authorized the use of Novo Nordisk’s well-known weight-loss medication Wegovy, the Danish pharmaceutical behemoth announced. Beijing has approved the ground-breaking treatment for those who are overweight or obese and have at least one weight-related... -
Novo Nordisk notched a win in race to boost output of obesity drug Wegovy, with its parent company announcing to buy Catalent
Feb 6, 2024Novo Nordisk notched a win on Monday in its race to boost output of its popular obesity drug Wegovy, with its parent company announcing it was buying Catalent, a key manufacturing subcontractor of the product, for... -
Novo Nordisk’s net profit soared by 51 percent last year
Feb 2, 2024Danish pharmaceutical giant Novo Nordisk, Europe’s most valuable company, said Wednesday its net profit soared by 51 percent last year, driven by sales of its popular diabetes and obesity drugs. Novo Nordisk reported a net profit... -
Novo Nordisk invests more than 16 billion Danish kroner in expansion of production facilities in Chartres, France
Dec 8, 2023Novo Nordisk today announced the investment of more than 16 billion Danish kroner (2.1 billion euros) starting in 20231 to expand the existing production site in Chartres, France, for the current and future product portfolio within... -
Aspect Biosystems and Novo Nordisk enter partnership to develop bioprinted tissue therapeutics for diabetes and obesity
Apr 14, 2023Aspect Biosystems and Novo Nordisk A/S today announced a collaboration, development, and licence agreement to develop bioprinted tissue therapeutics designed to replace, repair, or supplement biological functions inside the body with the aim of delivering a... -
Novo Nordisk and Microsoft collaborate to accelerate drug discovery and development using big data and artificial intelligence
Sep 14, 2022Novo Nordisk and Microsoft have entered a new strategic collaboration to combine Microsoft’s computational services, cloud and artificial intelligence (AI) with Novo Nordisk’s drug discovery, development and data science capabilities. Through the partnership, Microsoft is providing... -
Novo Nordisk and the University of Toronto announce joint 200 DKK million investment to address diabetes and chronic disease prevention
Apr 18, 2021Novo Nordisk A/S and the University of Toronto (U of T) has announced a DKK 200 million (CAD 40 million) investment to establish the Novo Nordisk Network for Healthy Populations. The network will focus on new... -
World’s largest study of cardiovascular disease in T2D shows need for improved knowledge and disease management
Sep 26, 2020Novo Nordisk announced the results of the CAPTURE study, a global non-interventional study to uncover the prevalence of cardiovascular disease and risk and its management in people living with type 2 diabetes. The study, the first... -
Novo Nordisk to acquire Corvidia Therapeutics
Jun 15, 2020Novo Nordisk A/S declared that it’s entered into a definitive deal to buy Corvidia Therapeutics Inc., a privately held, clinical stage company which is focused on the research and development of transformative therapies for cardio-renal diseases....
